Time filter

Source Type

Koulaouzidou E.A.,Aristotle University of Thessaloniki | Touplikioti P.,Applied Molecular Oncology Laboratory | Ziouti F.,Applied Molecular Oncology Laboratory | Papazisis K.T.,Applied Molecular Oncology Laboratory
Dental Materials Journal | Year: 2013

Dental bonding agents may affect the cell cycle patterns and induce cell cycle arrest by blocking its progression. This study tested the cell cycle effects through cyclin-dependent kinase (cdc2) and Rb phosphorylation. Human lung fibroblasts (MRC5) were used for the experiments. The bonding agent tested was the total-etch XP bond. Extracts of the bonding agent were prepared and serial dilutions were tested. The effects of the bonding agent on cell survival, proliferation and DNA synthesis were tested by the SRB and BrdU assays. Analysis of cell cycle distribution was performed by flow cytometry. XP bond exhibited strong inhibition of DNA synthesis and after 48 h of exposure cells were accumulated in the G2/M phase. Cells exposed to the half maximal cell growth inhibitory concentration (IC50) showed an increase in cdc2 kinase and Rb phosphorylation. The results most likely indicate mutagenic effect of the tested agent. Source

Kesisis G.,Applied Molecular Oncology Laboratory | Kesisis G.,Democritus University of Thrace | Kontovinis L.F.,Applied Molecular Oncology Laboratory | Kontovinis L.F.,Democritus University of Thrace | And 2 more authors.
Journal of B.U.ON. | Year: 2010

In this review we will provide a synopsis of the biological markers used in the care of breast cancer patients with emphasis on clinical application. The advent of molecular technology has incorporated new biomarkers along with the older immunohistochemical and serum ones. Serum tumor markers are proteins shed from breast cancer cells. Their levels have long been used as a measure of tumor burden and disease progression or recurrence. However, limitations exist that should be known to those involved in breast cancer management. Historically, immunohistochemical markers have been used to guide treatment decisions. These markers reveal characteristics of the cancer cells and have been used both as prognostic and predictive factors. Molecular markers give information on the expression of certain genes in tumor tissues related to proliferation, invasion, and metastasis and researchers try to correlate them with the use of mathematical modeling with clinical outcomes, hence those markers exhibit prognostic and predictive significance. All these tools can guide personalized treatment by estimating patient prognosis and risk of relapse and tailor accordingly therapeutic approaches. © 2010 Zerbinis Medical Publications. Source

Laschos K.A.,Applied Molecular Oncology Laboratory | Papazisis K.T.,Applied Molecular Oncology Laboratory | Kontovinis L.F.,Applied Molecular Oncology Laboratory | Kalaitzis C.,Democritus University of Thrace | And 3 more authors.
Journal of B.U.ON. | Year: 2010

New targeted agents have become the mainstream of treatment in metastatic renal cell carcinoma (mRCC) and substituted the previous cytokine-based therapies. Vascular endothelial growth factor (VEGF) pathway is the principle target for drugs like sunitinib, sorafenib and bevacizumab. As VEGF is regulating dendritic cell (DC) function, inhibition of VEGF results in activation of DCs and a shift towards cellular (type 1) immunity, which is believed to favor cancer rejection. Recent studies have established the immune-stimulating effects of sunitinib that may as well be a marker for effectiveness. On the other hand, sorafenib not only inhibits VEGF receptor (VEGFR) but is also a B-Raf inhibitor (a component of the ras - MAPK pathway) and this leads to downregulation of immune responses. Sorafenib has not yet shown benefit in first-line treatment of mRCC when compared to interferon (IFN)-α. and sorafenib-mediated immunosuppression may partially account for that. Mammalian target of rapamycin (mTOR), the target of temsirolimus, is an element of the DC activation pathway. There are no data for in vivo effects oftemsirolimus in the immune system. The addition of IFN-α to temsirolimus resulted in inferior outcomes than temsirolimus alone. IFN-α has however still a place in mRCC treatment, as bevacizumab has been approved in combination with IFN-α. New clinical trials address the effects of the combination of cytokines with targeted agents. The immune-modulating effects of targeted treatments may be important in pharmacodynamic outcomes, effectiveness or the development of adverse events. © 2010 Zerbinis Medical Publications. Source

Discover hidden collaborations